Fosun Pharmaceutical Gets FDA Green Light for HLX42 ADC Clinical Study
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has received approval from the US...
SHA: 600196
Fosun Pharmaceutical’s FCN-437c filing Accepted for Review by China’s NMPA
Shanghai-based Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) has announced that the National...
Fosun Pharmaceutical’s US Subsidiary Partners with Treehill Partners for Clinical-Stage Investments
Fosun Pharmaceutical (Group) Co., Ltd (HKG: 2196; SHA: 600196) through its US subsidiary, Fosun Pharma...
Fosun Pharmaceutical Secures Clinical Trial Approvals for VT-101 in China and the US
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced receiving clinical trial approvals for...
CIIE 2023: Danaher, Boehringer-Ingelheim, Merck, J&J, BeiGene, and Fosun Pharma Announce China Partnerships
The 6th China International Import Expo (CIIE) held in Shanghai this week has been a...
Fosun Pharmaceutical and Insightec Collaborate on Non-Invasive Brain Treatment Technology
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced a strategic partnership with Israel-based...
Intuitive Surgical-Fosun Medical Launches Da Vinci Xi Surgical Robot at CIIE
Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd, a joint venture between Shanghai Fosun Pharmaceutical (Group)...
Fosun Pharma Gains NMPA Approval for Clinical Trials of HLX42 and HLX43 ADCs
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced that it has received approval...
Fosun Pharma Gains NMPA Approval for Phase I Trial of XS-03 in Advanced Solid Tumors
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has...
Shanghai Henlius Receives GMP Certification from ANVISA for Biosimilar Manufacturing
China-based Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary Shanghai Henlius Biotech,...
Fosun Pharmaceutical to Acquire 14% Stake in UnitedHealthcare for USD 34 Million
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has announced plans to invest RMB 248.9...
Fosun Pharma Initiates Phase III Trial for ET-26 Anesthetic in China
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a leading healthcare conglomerate in China, has...
Fosun Pharma’s Serplulimab Approved for Esophageal Squamous Cell Carcinoma and Grafalon for GvHD Study
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196) has issued updates on the development statuses...
Fosun Pharma Reports Moderate Revenue Growth and Increased R&D Spend in 2023 Interim Report
Fosun Pharma (SHA: 600196) has released its 2023 interim financial report, recording revenues of RMB...
Fosun Pharma Adjusts Investment Allocation for 2022 Non-Public Offering Projects
Fosun Pharma (SHA: 600196) has declared adjustments to the investment amounts for some of its...
Pingshan District and Fosun Pharma Ink Strategic Deal to Boost Biomedical Industry
The People’s Government of Pingshan District in Shenzhen has signed a cooperation framework agreement with...
Shanghai Henlius Completes Phase I/II Study for Anti-VEGF mAb HLX04-O in Wet AMD
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196, HKG: 2196) subsidiary, Shanghai Henlius Biotech, Inc....
Biotherus Inc. and BioNTech SE Enter Global License Agreement for Cancer Therapies
China-based biotech company Biotheus Inc. has announced a strategic research collaboration, option, and worldwide license...
Shanghai Fosun Pharmaceutical Submits Tenapanor Approval Application to China’s NMPA
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...
Shanghai Fosun Pharmaceutical Submits Daxibotulinumtoxin A (RT002) for NMPA Approval
Shanghai Fosun Pharmaceutical (Group) Co., Ltd (SHA: 600196), a China-based pharmaceutical company, has announced a...